Want to see HK:2315 full AI Analyst Report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Stock Forecast & Price Target
2315 Analyst Ratings
There are no analyst ratings in the last 3 months.
2315 Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
2315 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 1 | 0 | 0 |
In the current month, 2315 has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2315 average Analyst price target in the past 3 months is ―.
2315 Financial Forecast
2315 Earnings Forecast
Next quarter’s earnings estimate for 2315 is HKD 0.19 with a range of ― to ―. The previous quarter’s EPS was HKD 0.19. 2315 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 2315 has Performed in-line its overall industry.
2315 Sales Forecast
Next quarter’s sales forecast for 2315 is HKD 0 with a range of ― to ―. The previous quarter’s sales results were ―. 2315 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 2315 has Performed in-line its overall industry.